Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266220, C514S210210, C514S217060, C514S313000, C540S599000, C540S600000, C544S284000, C546S144000, C546S159000
Reexamination Certificate
active
11100938
ABSTRACT:
Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
REFERENCES:
patent: 4012513 (1977-03-01), Birchall et al.
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 5104884 (1992-04-01), Korodi et al.
patent: 5444062 (1995-08-01), Coe et al.
patent: 5605900 (1997-02-01), Fujiwara et al.
patent: 5686458 (1997-11-01), Lee et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: 1308439 (2003-05-01), None
patent: WO86 06721 (1986-11-01), None
patent: WO97 09308 (1997-02-01), None
patent: WO99/34786 (1999-07-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 01 02385 (2001-01-01), None
Thompson et al., J. Org.Chem. 49, pp. 5237-5243 (1984).
Ishiyama et al., J. Org. Chem. 60, pp. 7508-7510 (1995).
Miyaura et al., Chem. Rev. 95, pp. 2457-2483 (1995).
J. K. Stille, Angew. Chem. 98, 508-524 (1986).
S. P. Stanford, Tetrahedron 54, pp. 263-303 (1998).
Widdowson et al., Tetrahedron 42, pp. 2111-2116(1986).
E. I. Negishi, Acc. Chem. Res. 15, pp. 340-348 (1982).
Webber et al., J. Med. Chem. 36, pp. 733-746 (1993).
Chem. Abstracts, XP002190201 for Heterocycl. Commun., Korodi, Ferenc, 1(1), pp. 59-68 (1994).
Chem. Abstracts, XP002190202 for Farmaco, Savini, Luisa, et al., 49(10), pp. 633-639 (1994).
Chem. Abstracts, XP 002190203 for Arch., Pharm., Sathi Garima, et al., 316(9), pp. 767-772 (1983).
Chem. Abstracts, XP002190204 for Khim.-Farm. Zh., Yakhontov., L.N., et al., 9(11), pp. 12-18 (1975).
CA 122:132333, abstract, 1997.
CA 122:71356, abstract, 1997.
CA 99:175562, abstract, 1999.
CA 84:43975, abstract, 1976.
Breu Volker
Dautzenberg Frank
Guerry Philippe
Nettekoven Matthias Heinrich
Pflieger Philippe
Coleman Brenda
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
Neuropeptide Y antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuropeptide Y antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropeptide Y antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745236